STT3A Monoklonaler Antikörper

STT3A Monoklonal Antikörper für IHC, WB,ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, IF, ELISA

Konjugation

Unkonjugiert

Publikationen

2

CloneNo.

1E2B12

Kat-Nr. : 66581-1-Ig

Synonyme

B5, Integral membrane protein 1, ITM1, STT3 A, STT3A, TMC, Transmembrane protein TMC

---

Galerie der Validierungsdaten

• 

  WB analysis of THP-1 using 66581-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 66581-1-Ig (STT3A antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human breast cancer using 66581-1-Ig

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 66581-1-Ig (STT3A antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 66581-1-Ig

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 66581-1-Ig (STT3A antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: THP-1-Zellen, HEK-293-Zellen, HL-60-Zellen, K-562-Zellen, RAW 264.7-Zellen
• Erfolgreiche Detektion in IHC: humanes Mammakarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:6000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• IHC: See 2 publications below
• IF: See 1 publications below

Produktinformation

66581-1-Ig bindet in WB, IHC, IF, ELISA STT3A und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: STT3A fusion protein Ag27072
• Vollständiger Name: STT3, subunit of the oligosaccharyltransferase complex, homolog A (S. cerevisiae)
• Berechnetes Molekulargewicht: 705 aa, 81 kDa
• Beobachtetes Molekulargewicht: 65 kDa
• GenBank-Zugangsnummer: BC020965
• Gene symbol: STT3A
• Gene ID (NCBI): 3703
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

STT3A, also named as Integral membrane protein 1, belongs to the STT3 family. STT3A is expressed at high levels in placenta, liver, muscle and pancreas, and at very low levels in brain, lung and kidney. STT3A is a catalytic subunit of the N-oligosaccharyl transferase (OST) complex which catalyzes the transfer of a high mannose oligosaccharide from a lipid-linked oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains. STT3A is present in the majority of OST complexes and mediates cotranslational N-glycosylation of most sites on target proteins, while STT3B-containing complexes are required for efficient post-translational glycosylation and mediate glycosylation of sites that have been skipped by STT3A. There are two isoforms of STT3A with molecular weight of 81 and 70 kDa. 66581-1-Ig antibody detects a protein around 65-70 kDa in SDS-PAGE which is similar to papers published. (PMID: 32005703, 25135935)

Publikationen

Species	Application	Title
human	IHC	Transl Lung Cancer Res; Targeting STT3A produces an anti-tumor effect in lung adenocarcinoma by blocking the MAPK and PI3K/AKT signaling pathway.; Authors - Jiahan Cheng
human	IHC,IF	Front Immunol; Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer.; Authors - Wenchang Lv